



CHF Solutions, Inc. Fulfills First Commercial Orders for Italy and Asia

May 14, 2018

EDEN PRAIRIE, Minn., May 14, 2018 (GLOBE NEWSWIRE) -- CHF Solutions, Inc. (Nasdaq:CHFS) announced today that it has received and fulfilled first commercial orders from its distributor in Italy, TRX Italy, S.r.l. The company has also fulfilled orders previously received from its distributor in Asia, Transmedic, for customers in Singapore and Hong Kong.

These initial shipments support the strategy execution of the company's distributor partners, which have initiated the restart of Aquadex Flexflow® therapy into four target accounts in Italy and four additional accounts in Singapore. The orders from Hong Kong represent the company's introduction into that market.

"We have regularly emphasized our dedication to addressing the international problem of fluid overload for acute decompensated heart failure patients outside the United States," commented John Erb, chairman and chief executive officer of CHF Solutions. "Having announced our distribution agreements in both Western Europe and Asia, the fulfillment of these initial shipments underscores our intention to provide physicians worldwide with a clinically proven, alternative therapy for the treatment of fluid overload when diuretics have ceased to be effective."

About CHF Solutions

CHF Solutions, Inc. (NASDAQ:CHFS) is a medical device company focused on commercializing the Aquadex FlexFlow system for Aquapheresis® therapy. The Aquadex FlexFlow system is indicated for temporary (up to eight hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy, and extended (longer than 8 hours) ultrafiltration treatment of patients with fluid overload who have failed diuretic therapy and require hospitalization. All treatments must be administered by a healthcare provider, under physician prescription, both of whom having received training in extracorporeal therapies. The company's mission is to predict, measure, and control patient fluid balance through science, collaboration, and innovative medical technology. CHF Solutions is a Delaware corporation headquartered in Minneapolis, Minnesota with wholly owned subsidiaries in Australia and Ireland. The company has been listed on the NASDAQ Capital Market since February 2012.

CONTACTS:

INVESTORS:

Claudia Napal Drayton
Chief Financial Officer
CHF Solutions, Inc.
952-345-4205
ir@chf-solutions.com

-or-

Bret Shapiro
Managing Partner
CORE IR
516-222-2560
brets@coreir.com
www.coreir.com

MEDIA

Jules Abraham
JQA Partners, Inc.
917-885-7378
jabraham@jqapartners.com

[Primary Logo](#)

Source: CHF Solutions, Inc.